(Total Views: 334)
Posted On: 05/30/2018 12:08:41 PM
Post# of 30015
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
I think the option to license the data for Lympro is being used to package Lympro for a private placement or under the best case scenario, possibly a partnership. They don't have any money to pay for the license until they get a funding, and they haven't even put together the lympro subsidiary yet. So they are sort of putting the cart before the horse. They can't finalize a negotiation at this point, because they don't have any funds to close on whatever deal they negotiate. They just have the data. So I assume whatever license they put together will be tied to some kind of funding/partnership they can create. I also think it's telling in the pr:
"prospective collaborators noted that what was missing from our initial dataset was the use of a reference standard that incorporated newly available biomarkers,"
"prospective collaborators noted that what was missing from our initial dataset was the use of a reference standard that incorporated newly available biomarkers,"
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)